Psyence Biomedical Ltd. - Common Shares (PBM)
PBM moved a median of -1.73% 30 minutes after news, and -2.58% by the close. How PBM actually reacts to news — the realized, point-in-time move the market made, measured across 192 labeled events over the last three years with zero look-ahead.
PBM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.69% | 33% | 187 |
| 30-min | -1.73% | 30% | 191 |
| 60-min | -2.09% | 30% | 191 |
| to close | -2.58% | 36% | 191 |
| Middle 50% of PBM reactions | -5.27% to +0.73% |
|---|---|
| Median reaction (30-min) | -1.73% |
| Measured reactions | 192 |
Half of all Psyence Biomedical Ltd. - Common Shares news events land between -5.27% and +0.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when PBM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PBM's baseline. Nothing else.
Recent PBM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Oct 05 | SEC filing · Form 6-K | SEC EDGAR | +1.33% | -3.60% | |
| Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine | Press release | GlobeNewswire | +1.33% | -3.60% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 28 | SEC filing · Form 6-K | SEC EDGAR | -0.29% | +1.34% | |
| Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation | Press release | GlobeNewswire | -0.29% | +1.34% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 23 | SEC filing · Form 6-K | SEC EDGAR | +1.11% | +7.50% | |
| Psyence BioMed Announces Strategic Ibogaine Investment | Press release | GlobeNewswire | +1.11% | +7.50% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 14 | SEC filing · Form 6-K | SEC EDGAR | +3.43% | +11.32% | |
| Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development | Press release | GlobeNewswire | +3.43% | +11.32% | |
| Form EFFECT PSYENCE BIOMEDICAL LTD. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.46% | |
| Form F-3 PSYENCE BIOMEDICAL LTD. | SEC filing · Form F-3 | SEC EDGAR | +0.22% | +0.94% | |
| Form S-8 PSYENCE BIOMEDICAL LTD. | SEC filing · Form S-8 | SEC EDGAR | +0.22% | +0.94% | |
| Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development | Press release | GlobeNewswire | -2.92% | -7.87% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Aug 06 | SEC filing · Form 6-K | SEC EDGAR | -1.64% | -3.61% | |
| Form 20-F PSYENCE BIOMEDICAL LTD. For: Mar 31 | SEC filing · Form 20-F | SEC EDGAR | -2.26% | -6.13% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Jun 05 | SEC filing · Form 6-K | SEC EDGAR | +0.28% | +1.98% | |
| Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing | Press release | GlobeNewswire | -1.76% | -2.58% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 23 | SEC filing · Form 6-K | SEC EDGAR | -6.76% | -19.61% | |
| Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder | Press release | GlobeNewswire | +3.85% | +5.37% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 17 | SEC filing · Form 6-K | SEC EDGAR | -5.16% | -16.97% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 20 | SEC filing · Form 6-K | SEC EDGAR | -2.73% | -14.26% | |
| Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source | Press release | GlobeNewswire | -2.73% | -14.26% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 17 | SEC filing · Form 6-K | SEC EDGAR | -2.73% | -14.26% | |
| Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | Press release | GlobeNewswire | -15.99% | -22.61% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | — | -1.71% | |
| Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities | Press release | GlobeNewswire | +0.00% | -6.04% | |
| Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone | Press release | GlobeNewswire | +1.63% | +1.22% | |
| Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial | Press release | GlobeNewswire | +0.00% | +5.58% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Mar 02 | SEC filing · Form 6-K | SEC EDGAR | -1.63% | +4.49% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Feb 19 | SEC filing · Form 6-K | SEC EDGAR | -17.87% | -13.23% | |
| Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment | Press release | GlobeNewswire | -17.87% | -13.23% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Feb 19 | SEC filing · Form 6-K | SEC EDGAR | -0.38% | -1.65% | |
| Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders | Press release | GlobeNewswire | -3.26% | -9.12% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Feb 13 | SEC filing · Form 6-K | SEC EDGAR | -3.26% | -9.12% | |
| Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway | Press release | GlobeNewswire | -3.26% | -9.12% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Feb 12 | SEC filing · Form 6-K | SEC EDGAR | -2.38% | -4.42% | |
| Psyence BioMed Announces Settlement of Shareholder Litigation | Press release | GlobeNewswire | +1.23% | -7.21% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Jan 29 | SEC filing · Form 6-K | SEC EDGAR | +3.84% | +4.43% | |
| Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | Press release | GlobeNewswire | +3.84% | +4.43% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Jan 27 | SEC filing · Form 6-K | SEC EDGAR | -1.68% | -3.43% | |
| Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 | Press release | GlobeNewswire | — | -0.05% | |
| Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date | Press release | GlobeNewswire | — | — | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Jan 14 | SEC filing · Form 6-K | SEC EDGAR | -6.93% | -5.54% | |
| Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split | Press release | GlobeNewswire | -6.93% | -5.54% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Jan 13 | SEC filing · Form 6-K | SEC EDGAR | +0.42% | -2.19% | |
| Form 6-K/A PSYENCE BIOMEDICAL LTD. For: Jan 12 | SEC filing · Form 6-K | SEC EDGAR | +0.42% | -2.19% | |
| Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity | Press release | GlobeNewswire | +0.70% | +0.59% | |
| Form 6-K PSYENCE BIOMEDICAL LTD. For: Jan 08 | SEC filing · Form 6-K | SEC EDGAR | +2.66% | +4.85% | |
| Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash | Press release | GlobeNewswire | -2.74% | -11.51% | |
| Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial | Press release | GlobeNewswire | -5.14% | -31.51% | |
| Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science | Press release | GlobeNewswire | -1.70% | -10.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PBM section they belong to.
Where else PBM is measured.
PBM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Psyence Biomedical Ltd. - Common Shares's median reaction calculated?
Every labeled PBM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 192 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 30% of PBM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PBM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.